Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models.

ABSTRACT:

Objectives

Following a maintenance course of rituximab (RTX) for ANCA-associated vasculitis (AAV), relapses occur on cessation of therapy, and further dosing is considered. This study aimed to develop relapse and infection risk prediction models to help guide decision making regarding extended RTX maintenance therapy.

Methods

Patients with a diagnosis of AAV who received 4-8 grams of RTX as maintenance treatment between 2002 and 2018 were included. Both induction and maintenance doses were included; most patients received standard departmental protocol consisting of 2× 1000 mg 2 weeks apart, followed by 1000 mg every 6 months for 2 years. Patients who continued on repeat RTX dosing long-term were excluded. Separate risk prediction models were derived for the outcomes of rela

SUBMITTER: McClure ME 

PROVIDER: S-EPMC7937025 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature